SCHEMBL5758908

SCHEMBL5758908

CCCCCN(CCO)S(=O)(=O)c1ccc(Cc2ccc3oc(=O)cc(C(F)(F)F)c3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.39
LMNA P02545 2/20 0.39
VCAM1 P19320 1/20 0.37
CNR2 P34972 5/20 0.37
MCL1 Q07820 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP1B1 Q16678 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PPARA Q07869 2/20 0.35
HSD17B3 P37058 1/20 0.35
AR P10275 3/20 0.35
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757204 0.97 LMNA (0.41) TP53LMNAVCAM1MCL1ALDH1A1
SCHEMBL5761174 0.94 MCL1 (0.37) TP53LMNAMCL1ALDH1A1MAPT
SCHEMBL5761676 0.93 LMNA (0.44) TP53LMNAVCAM1MCL1ALDH1A1
SCHEMBL5760662 0.90 KDM4E (0.41) TP53LMNACNR2MCL1ALDH1A1
SCHEMBL5758868 0.85 NR1H4 (0.43) LMNACNR2ALDH1A1MAPTTSHR
SCHEMBL5860102 0.85 AR (0.39) TP53LMNAMCL1ALDH1A1GAA
SCHEMBL5860528 0.81 AR (0.40) CNR2ALDH1A1CYP1A1CYP1A2CYP1B1
SCHEMBL5761340 0.80 MEN1 (0.39) LMNACNR2MCL1ALDH1A1NPSR1
SCHEMBL5762598 0.80 TSHR (0.50) TP53LMNACNR2ALDH1A1MAPT
SCHEMBL5761235 0.79 AR (0.46) CNR2TSHRNPSR1ARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT TP53 1975/4885LMNA 3279/4885VCAM1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.